Compare Box Inc (BOX) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Box Inc vs TG Therapeutics Inc — how do they compare? Box Inc trades at $32.5 (market cap $4.55B), while TG Therapeutics Inc trades at $49.59 (market cap $7.64B). The key difference: TG Therapeutics Inc is the larger of the two by market cap, and Box Inc is trading nearer its 52-week high, TG Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| BOX | TGTX | |
|---|---|---|
Market Cap | $4.55B | $7.64B |
Sector | Technology | Health |
52-Week High | $33.60 | $59.06 |
52-Week Low | $21.37 | $26.94 |
Enterprise Value | $5.10B | $7.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BOX trades at $32.53, down 3.18% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $37.00. Revenue grew to $1.09 billion in 2025 with a net income margin of 22.43%, though the P/E ratio of 51.3 indicates a premium valuation. Recent news highlights Box's partnership with Quintas Energy for an AI-ready content platform, reinforcing its enterprise focus.
The outlook is positive with strong analyst support (60.72% buy ratings) and projected revenue growth to $1.2 billion in 2026. Risks include high valuation multiples and competitive pressures in cloud content management. Upside potential exists if earnings beat expectations, but investors should monitor debt levels and margin sustainability.
TG Therapeutics (TGTX) trades at $49.66, up 1.02% on the day, with a bearish technical signal and recent earnings misses despite strong revenue growth. The company reported Q2 2026 revenue of $240 million and raised full-year BRIUMVI guidance to $950 million, but net income was impacted by manufacturing investments. Valuation ratios show a high P/E of 18.22 and EV/EBITDA of 56.26, while profitability metrics like ROE of 100.28% remain robust.
Outlook is mixed: strong product demand and raised revenue targets support growth, but earnings volatility and a bearish technical trend pose risks. Analyst consensus is bullish with an $63.75 price target, though legal investigations and competitive pressures require monitoring for stock investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Box Inc
Box is a cloud-based content services platform that provides cloud-based storage and workflow collaboration services for enterprise customers. The firm was founded in 2005 as a file sync and sharing provider. More recently, however, the company has focused on bolstering its product portfolio by adding tools such as governance and e-signature that enhance workflow management and collaboration.
Read more on BOX →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
